Press Releases
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Corbus Pharmaceuticals Set to Join Russell Microcap® Index
Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
